InMed receives Nasdaq minimum bid price deficiency notice By Investing.com

Nasdaq notified InMed (NASDAQ:INM) that its shares failed the $1.00 minimum bid-price rule after 30 consecutive trading days; the stock trades at $0.66 (down 74% over the past year) with a market capitalization of $2.59M. InMed has 180 calendar days to regain compliance by achieving a $1.00+ close for 10 consecutive business days (with a potential additional 180-day extension) or face possible delisting and trading suspension during any appeal. The company says it will monitor options, including a reverse stock split, and InvestingPro flags the shares as undervalued per its Fair Value models. Separately, InMed reported preclinical data for INM-901 showing reduced neuroinflammation in 3D human brain organoid Alzheimer’s models; no clinical trial start date has been announced.

Analysis

Small-cap biotech mechanics are the key driver here: funding risk, listing friction and retail positioning interact to create outsized volatility independent of science. A likely near-term feedback loop is funding uncertainty → heightened selling pressure → dilutive financing terms if raised quickly, which amplifies downside and raises the hurdle for any positive clinical signal to move the shares meaningfully.

Market-structure secondaries matter more than the preclinical result for months: if access to capital is constrained, strategic acquirers with cash become the marginal marginal buyer, which compresses expected takeover premia and shifts value to milestone/royalty structures. Separately, passive/smart-beta rules and prime-broker collateral policies can force mechanical selling well before any clinical binary, so trading flows — not fundamentals — are the dominant short-term risk.

The true optionality lies in the science-to-clinic path but with very low base rates; treat upside as binary and low probability. A practical horizon segmentation: days–weeks dominated by listing/financing flow, 3–12 months dominated by capital planning and IND/clinical-readout milestones, and 12+ months in the realm of M&A/partnering if data supports translation. Tail risks include a dilutive PIPE at distressed pricing, regulatory suspension of trading, or conversely a strategic buyout at favorable terms to holders who remain through financing events.

Key Decisions for Investors

• Event-driven short-sized exposure: establish a small tactical short of INM (size 0.1–0.25% NAV) via borrow or liquid puts (30–90 day expiries) to capture downside from financing/listing pressure; trim into spikes and cap loss at 50% of notional if shares gap up on a partnership announcement.
• Hedge-biotech pair: short INM and long a diversified biotech ETF (e.g., XBI) sized 1:4 to neutralize sector beta while isolating idiosyncratic downside; hold 3–6 months and reassess after any financing or reverse-split announcement.
• Opportunistic asymmetric long: allocate a de minimis option ticket (<=0.05% NAV) to deep OTM/LEAP calls only after a clearly non-dilutive partnership or IND filing is announced — expect 3–5x upside if clinical translation begins, probability-weight accordingly.
• Liquidity-risk defense: avoid buying stock ahead of any announced capital raise or listing remedy; if already long, require management to disclose financing terms before adding and set a stop at 25–35% below current cost to prevent forced liquidation cascades.